A key House committee has released a series reports for spending bills that include a wide range of marijuana-related provisions.
In directing federal agencies to reconsider firing federal workers for state-legal consumption, promote research into cannabis and fund CBD regulations, the reports make clear that marijuana has become a mainstream issue that congressional leadership is becoming more comfortable addressing in high-profile legislative documents.
The House Appropriations Committee directives are attached to spending bills that also contain legislative reform provisions, including previously reported proposals to protect state medical marijuana laws from federal interference and shield banks from being punished for working with cannabis businesses.
Here’s a look at the new report language that’s attached to appropriations legislation:
Marijuana use by federal employees
The Financial Services and General Government spending bill report directs the Office of Personnel Management to “review its policies and guidelines regarding hiring and firing of individuals who use marijuana in States” where cannabis is legal.
“Hiring Guidelines.—The Committee encourages OPM to review its policies and guidelines regarding hiring and firing of individuals who use marijuana in States where that individual’s private use of marijuana is not prohibited under the law of the State. These policies should reflect changes to the law on marijuana usage and clearly state the impact of marijuana usage on Federal employment.”
The report attached to the Labor, Health and Human Services, Education, and Related Agencies funding bill features a number of marijuana research provisions, including calling on the National Institutes of Health (NIH) to develop “a multipronged strategy wherein basic and clinical scientists and public health specialists work together to address the opportunities and challenges of cannabis in a comprehensive manner.”
“Cannabis Research.—NIH currently supports a diverse portfolio of research on cannabinoids and the endocannabinoid system, yet this research support typically relies on narrowly tailored program announcements and grants rather than a multipronged strategy wherein basic and clinical scientists and public health specialists work together to address the opportunities and challenges of cannabis in a comprehensive manner. The Committee encourages NIDA to continue supporting a full range of research on the health effects of marijuana and its components, including research to understand how marijuana policies affect public health, to help inform marijuana policymaking in States.”
Members also made a recommendation to provide protections for universities that conduct research into cannabis, noting the significant public interest in such studies.
“Protecting Scientific Research on Marihuana.—Through scientific research, institutions of higher education advance our understanding and knowledge of various aspects of our world. Moreover, when in the public interest, such institutions should be able to conduct such research without fear of reprisal or loss of Federal funding. This includes research on cannabis, a Schedule I controlled substance under the Controlled Substances Act. As more States and localities move to legalize cannabis, many institutions of higher education are expanding the knowledge-base on this controlled substance. As a result, the Committee notes that such research is in the public interest, and the recommendation includes new bill language prohibiting the Department from penalizing institutions of higher education that conduct scientific research on marihuana.”
The committee directed that $1 million should be appropriated for research into natural alternatives to opioids such as kratom and CBD, noting that the “wide availability and increased use of these substances” makes it “imperative to know more about potential risks or benefits, and whether or not they can have a role in finding new and effective non-opioid methods to treat pain.”
“Kratom.—The Committee notes that little research has been done to date on natural products that are used by many to treat pain in place of opioids. These natural plants and substances include kratom and cannabidiol (CBD). Given the wide availability and increased use of these substances, it is imperative to know more about potential risks or benefits, and whether or not they can have a role in finding new and effective non-opioid methods to treat pain. The Committee recommends $1,000,000 for this research, an increase of $500,000 above the fiscal year 2020 enacted level, and encourages AHRQ to make center-based grants to address research which will lead to clinical trials in geographic regions which are among the hardest hit by the opioid crisis.”
In a section concerning opioid overdose prevention, legislators wrote that the Centers for Disease Control and Prevention (CDC) should continue its work while also investigating misuse of other substances, including stimulants and cannabis.
“Opioid Abuse and Overdose Prevention.—The Committee commends CDC for its leadership on combating opioid drug overdoses. The Committee encourages the Director to continue to implement these activities based on population-adjusted burden of disease criteria, including mortality data (age adjusted rate), as significant criteria when distributing funds for overdose prevention activities. The Committee recognizes that the substance misuse epidemic is shifting, with an increase in overdoses resulting from stimulants and other substances. The Committee urges for CDC to monitor, prevent, and reduce harms associated with drug use, misuse, and overdose, including opioids, stimulants, cannabis, and other emerging risks. The Committee appreciates efforts by CDC to ensure that funding for opioid abuse and overdose prevention reaches local communities to advance local understanding of the opioid overdose epidemic and to scale-up prevention and response activities as intended by Congress.”
Military veterans and cannabis issues
Like last year, the panel noted in a report attached to the Military Construction, Veterans Affairs and Related Agencies spending bill that veterans have been denied home loan benefits from the U.S. Department of Veterans Affairs (VA) due to their work in the state-legal marijuana market. However, the department told Congress last month that it does not have a policy on the books stipulating that such employment renders veterans ineligible on its own; rather, it blamed conflicting state and federal laws for creating risk that makes it less likely for those in the industry to be eligible under the rules of private lenders.
The committee said it now wants VA to “improve communication with eligible lending institutions to reduce confusion among lenders and borrowers on this matter.”
“Home Loan Income Verification.—The Committee is aware of the Department’s denial of home loan guarantees to Veterans solely on the basis of the Veteran’s documented income being derived from state-legalized cannabis activities, and has previously expressed concern that confusion on this issue hinders Veterans’ ability to fully understand and consider how employment decisions could affect future eligibility for earned benefits. The Committee understands that as directed by House Report 116–63, VA has clarified that nothing in VA statutes or regulations specifically prohibits a Veteran whose income is derived from state-legalized cannabis activities from obtaining a certificate of eligibility for VA home loan benefits. The Committee directs the VA to improve communication with eligible lending institutions to reduce confusion among lenders and borrowers on this matter.”
The spending bill report also requests an update on a congressionally mandated marijuana research project.
“Cannabis Research.—The Committee requests an update on the status of the study on cannabis research, as described in House Report 116–63.”
Hemp research and regulations
In the report attached to the Agriculture, Rural Development, Food and Drug Administration and Related Agencies spending bill, the committee said it’s aware of difficulties hemp farmers face in ensuring their crops do not contain excess concentrations of THC and recognizes “that these challenges are exacerbated by lack of information, best practices, and tools to control the hemp content of THC.” To that end, it directs the U.S. Department of Agriculture (USDA) to issues report to Congress with data on crops having to be destroyed due to excess potency.
“Hemp.—The Committee is aware of the difficulty farmers face in trying to control the legal tetrahydrocannabinol (THC) content of their hemp. The Committee recognizes that these challenges are exacerbated by lack of information, best practices, and tools to control the hemp content of THC. The Committee directs USDA to report to Congress on the number of acres of hemp, by state that have been required to be destroyed because the crop exceeds the limit 0.3 percent THC content; the number of producers, by state, who are found to have a negligent violation of the 0.3 percent limit; and the total number, by state, of producers whose hemp has been tested for THC.”
Another provision of the report states that USDA should conduct “genomics and bioinformatics” studies into hemp in order to identify “the genetic control of key production and product quality traits” of the crop.
“Hemp Whole-Genome Bioinformatics.—The Committee encourages ARS to conduct genomics and bioinformatics research in collaboration with capable institutions to elucidate the genetic control of key production and product quality traits of the hemp plant. In addition, the Committee also encourages ARS to partner with institutions already engaged in such research to conduct hemp genetic improvement research and breeding with new breeding and editing techniques.”
Due to the increasing demand for hemp products, members called for $1.5 million in additional funding “to maintain the hemp germplasm repository.” They’re also seeking to appropriate about $41 million for a variety of initiatives including one concerning cannabis and cannabinoids.
“Industrial Hemp Germplasm.—The Committee recognizes the increasing demand for industrial hemp for a variety of uses and its growing importance as a crop for U.S. farmers. The Committee provides an additional $1,500,000 above the fiscal year 2020 level to maintain the hemp germplasm repository.”
“The Committee recommendation includes a net increase of $40,828,000, including increases for the following programs or initiatives: Strengthening Response Capabilities for Foodborne Outbreaks; Cannabis and Cannabis Derivatives; Artificial Intelligence and Other Emerging Technologies; Transform Medical Device Safety, Cybersecurity, Review, and Innovation; Compounding; and Modernizing Influenza Vaccines.”
Further, the report stipulates that USDA should adhere to the intent of Congress and make sure that hemp businesses are eligible for all competitive grant programs that are available to farmers and producers of other crops.
“Industrial Hemp.—The intent of Congress in Public Law 115–334 was for industrial hemp to be eligible for all USDA programs, including Rural Development. Industrial hemp can significantly benefit struggling rural economies. The Committee encourages Rural Development to ensure that industrial hemp is eligible for all competitive grant programs.”
And finally, the panel said that another $5 million should be made available to the Food and Drug Administration (FDA) for CBD enforcement and to develop regulations to permit the substance’s lawful marketing in the food supply or as a dietary supplement.
“Cannabidiol Enforcement.—The Committee provides an increase of $5,000,000 for enforcing the law to protect patients and the public while also providing a potential regulatory pathway for cannabis and cannabis derived products. The Committee maintains its concern about the proliferation of foods and dietary supplements marketed in violation of the Federal Food, Drug and Cosmetic Act (FFDCA), including products containing cannabis and cannabis-derived ingredients. Non-FFDCA-compliant products continue to pose potential health and safety risks to consumers through unsubstantiated and misleading claims such as treating a wide-range of life-threatening diseases and conditions. The Committee expects the FDA to continue to prioritize consumer-safety through application of the law.”
Curbing illegal marijuana grows on public land
Lawmakers again emphasized in the report for the Interior, Environment, and Related Agencies bill that they’re aware of illegal marijuana cultivation on public lands in California and said that these “activities harmfully impact the public, water, soil, and wildlife.”
“MARIJUANA ON PUBLIC LANDS – The Committee is aware that trespassers illegally grow marijuana on public lands in California. These unlawful activities harmfully impact the public, water, soil, and wildlife. The Committee supports Forest Service efforts to develop tools to detect and eradicate grow sites. The Committee directs the Forest Service and Bureau of Land Management to continue to cooperate with state, local and tribal governments on survey, reclamation, and prevention efforts to the maximum extent possible.”
Addressing marijuana-impaired driving
The Commerce, Justice, Science, and Related Agencies report alleges that instances of impaired driving have “spiked” in states that have legalized marijuana and says it wants the Justice Department to “assist states in identifying detection technologies that show promise in identifying drivers impaired by marijuana.”
“Marijuana-Impaired Drivers.—With the proliferation of state laws legalizing recreational and medical marijuana, the incidence rate of impaired driving has spiked. The Committee encourages the Department to assist states in identifying detection technologies that show promise in identifying drivers impaired by marijuana.”
In the Transportation, and Housing and Urban Development, and Related Agencies bill report, the committee also addresses impaired driving issues, saying it remains “concerned with the growing problem of people driving under the influence of one or multiple substances, including marijuana and opioids” and urges federal coordination to develop technologies that can detect active impairment from cannabis. The panel recognizes that doing so will likely not be achievable in the short-term, and so it mandates continued support for drug recognition expert training in the interim.
“Drug-impaired driving.—The Committee remains concerned with the growing problem of people driving under the influence of one or multiple substances, including marijuana and opioids. The Committee supports the goal of developing a reliable standard for all types of impaired driving and urges NHTSA to coordinate research efforts with states and other partners. At the same time, the Committee recognizes that developing a standard measurement of marijuana impairment, similar to blood alcohol concentration (BAC), remains unlikely in the near term. The Committee directs NHTSA to continue to robustly support Drug Recognition Expert (DRE) and Advanced Roadside Impaired Driving Enforcement (ARIDE) training and to prioritize the study and development of a standardized field sobriety test (SFST) to detect marijuana impairment.
“The Committee directs NHTSA to work with the Department of Justice, the Department of Health and Human Services, and the Department of Commerce to ensure that state highway safety offices and state law enforcement have the most up-to-date information from the Federal government on detecting impaired driving including an inventory of available technologies to detect recent drug use such as oral fluid technologies. In order to increase the safety of the transportation network by reducing drug-impaired driving, the Committee directs NHTSA to work with states to determine their toxicology testing and funding needs and to provide states with flexibility in how they use impaired driving countermeasures grants, including, but not limited to, assistance with state toxicology labs.”
Photo courtesy of Brian Shamblen.
Trump Campaign Orders Mississippi Medical Marijuana Activists To Cease Using President’s Name
President Donald Trump’s reelection campaign has issued a cease and desist order against a Mississippi medical marijuana legalization campaign, claiming “unauthorized and misleading representation” of the president’s position on the reform initiative in one of its mailers—even though he has on multiple occasions spoken favorably on camera about medical cannabis.
Michael Glassner, chief operating officer of Donald J. Trump for President Inc., sent a letter to Mississippians for Compassionate Care (MCC), demanding that they stop distributing campaign materials touting the president’s past remarks.
While the mailer and the envelope it’s being sent in don’t at any point state that Trump has specifically endorsed Initiative 65, they encourage voters to “join President Trump and 3 out of 4 Mississippi Republicans who support medical marijuana” and point out that he’s voiced “complete support for medical marijuana.”
It is indeed the case that the president has, on several occasions, stated that he’s in favor of medical cannabis reform.
For example, while he said in 2015 that Colorado has “a lot of problems going on right now” with its recreational marijuana program, medical cannabis “is another thing.”
“I think medical marijuana, 100 percent,” he said.
Beyond stating his personal support for medical cannabis, Trump has said multiple times that he personally knows people who have benefited from using it.
“I think medical should happen, right? Don’t we agree? I mean I think so,” he said at a 2015 rally in Nevada. “I know people that are very, very sick and for whatever reason, the marijuana really helps them.”
“I know people that have serious problems and they did that and it really does help them,” he said In a 2016 interview on Fox News.
But the president’s reelection campaign evidently takes issue with the state cannabis effort using his on-camera quotes.
“President Trump has never expressed support for Initiative 65, and his campaign demands that you immediately cease and desist all activities using the President’s name, image or likeness in support of the legalization of medical marijuana in Mississippi,” Glassner wrote in the October 12 letter, which was first reported by Y’all Politics.
“The President’s campaign strongly believes in and encourages your organization’s fundamental right to engage in speech on issues of public importance, but this is not about that,” he said. “You are misleadingly using the President’s name in support of your own agenda without authorization or justification.”
But MCC is defending the mailers, which also feature endorsements from multiple Republican legislators in the state.
“President Trump has clearly stated on multiple occasions that he supports medical marijuana. That is all that we’ve shared—the truth,” MCC Communications Director Jamie Grantham said in a press release. “The politicians and bureaucrats behind Mississippi Horizon clearly orchestrated this letter from the Trump campaign. It’s just the latest example of the lengths to which they will go to prevent any form of medical marijuana in Mississippi.”
“President Trump himself has said he supports medical marijuana and is letting the states decide,” she said. “Initiative 65 is the only plan on the ballot that will create an actual medical marijuana program in Mississippi.”
While Trump has made his views on medical cannabis clear—and he’s expressed support for a states’ right approach to marijuana policy—he’s also on several occasions released signing statements on spending legislation stipulating that he reserves the right to ignore a long-standing rider that prohibits the Justice Department from using its funds to interfere with state-legal medical marijuana programs.
He also proposed deleting the rider altogether in multiple annual budget proposals to Congress, though President Obama did the same thing when he was in office.
The Mississippi mailer neglected to acknowledge those nuances, however.
“For the last two years, he has signed legislation offered by Republican Senators to prevent his Department of Justice from prosecuting medical marijuana businesses in states that have legalized its use,” it states.
“The Trump campaign’s decision in this matter is a further indication that this administration is unwilling to either embrace or act upon marijuana policy reform,’ Justin Strekal, political director of NORML, told Marijuana Moment. “For four years, this administration has been silent at best and hostile at worst when it comes to marijuana policy, and there is no indication that they would change going forward if given the opportunity.”
“At the end of the day, this is just bad politics,” he said.
A Quinnipiac poll found last year that 93 percent of Americans support medical marijuana, including 86 percent of Republicans, 96 percent of Democrats and 96 percent of independents—raising questions about why the president’s reelection campaign chose to take the proactive step of distancing their candidate from such an overwhelmingly popular issue that enjoys supermajority backing across partisan lines.
Meanwhile, the Democratic presidential nominee, Joe Biden, favors legalizing medical marijuana, decriminalizing cannabis possession more broadly, expunging prior convictions, modestly rescheduling the drug under federal law and letting states set their own policies. That said, he helped craft some of the nation’s most infamously punitive anti-drug laws during his time in the Senate—a record that the Trump campaign has seized on.
“More than 81 percent of Mississippians agree with President Trump in supporting medical marijuana for people who are suffering,” Grantham said, referencing a poll released last month. “Voters see through the actions of politicians who failed to act on this issue and who are now trying to block this initiative. 65A lets politicians decide. More than 228,000 Mississippians signed petitions for Initiative 65 which lets doctors and patients decide.”
The medical cannabis reform campaign has faced a series of obstacles before and after qualifying for the state’s November ballot.
The primary complication for advocates is the fact that two competing initiatives will appear alongside each other on the ballot. After MCC qualified their measure, the legislature approved an alternative that is viewed as more restrictive. The result is a muddled ballot that requires voters to answer a two-step series of questions—and that potential confusion threatens to jeopardize the activist-led proposal.
More recently, the Mississippi State Medical Association and American Medical Association have also contributed to the opposition, circulating a sample ballot that instructs voters on how to reject Initiative 65.
Last week, Gov. Tate Reeves (R) signed legislation that amends state law to allow people to obtain marijuana-derived medications that are approved by the Food and Drug Administration. He also reiterated his opposition to broader medical cannabis reform, stating that he’s “against efforts to make marijuana mainstream.”
If the campaign’s measure passes, it would allow patients with debilitating medical issues to legally obtain marijuana after getting a doctor’s recommendation. The proposal includes 22 qualifying conditions such as cancer, chronic pain and post-traumatic stress disorder, and patients would be allowed to possess up to 2.5 ounces of marijuana per 14-day period.
In June, lawmakers introduced yet another medical cannabis alternative resolution that would’ve similarly posed a threat to the activist-driven reform initiative. But, to advocates’ relief, the legislation didn’t advance before lawmakers went home for the summer.
Read the Trump campaign’s cease and desist letter below:
New Jersey Voters Strongly Back Marijuana Legalization And Cannabis Pardons, New Poll Finds
Support for a referendum to legalize marijuana in New Jersey remains strong, according to a new poll released on Tuesday. And what’s more, voters want Gov. Phil Murphy (D) to go a step further by pardoning people with low-level cannabis convictions.
The survey, which is the fourth and final from the law firm Brach Eichler LLC this election cycle, shows that 65 percent of New Jersey voters are in favor of the reform proposal that will appear on the state’s November ballot. Just 29 percent are opposed to the policy change and six percent remain undecided.
These results are statistically consistent with the prior three polls from the firm as well as one from Fairleigh Dickinson University, which similarly found roughly two to one support for the measure. A separate survey released last week by Stockton University showed three to one support for legalizing cannabis among New Jersey voters.
As has historically been the case, Democrats are most likely to back legalization (70 percent), followed by independents (62 percent) and Republicans (52 percent).
But beyond legalizing cannabis for adult use, New Jersey voters are also strongly in favor of having the governor use his clemency powers for those previously convicted over low-level marijuana offenses. Sixty-eight percent of respondents said Murphy should grant those individuals pardons, compared to 21 percent who are against it and 11 percent who are unsure.
For the first time since the firm starting polling on cannabis issues this year, a majority of voters (51 percent) also said that prior marijuana records of all levels of convictions, rather than just simple possession, should be expunged.
“The Brach Eichler Cannabis Poll, which has consistently reported overwhelming support for legalizing cannabis, today again confirms that New Jersey voters support this long overdue change by a significant margin,” Charles Gormally, co-chair of the firm’s cannabis practice, said in a press release. “After election day it is imperative that our legislature move to create the most efficient, safe and regulated marketplace to capture the tri-state cannabis business.”
The survey, which involved interviews with 500 registered voters from October 5-13 and has a margin of error of +/- 4.4 percentage points, also asked about the policy of local control for the marijuana market. Forty-seven percent said that individual jurisdictions should be allowed to ban cannabis businesses from operating in their area, compared to 39 percent who are opposed to the proposal and 14 percent who are undecided.
“It is clear that home rule is a topic that needs to be more fully addressed,” Gormally said. “Cannabis businesses are going to need an immediate understanding of local politics and community issues before embarking on plans for certain parts of New Jersey.”
Five states have recreational or medical marijuana legalization on the ballot this election, and polling broadly indicates that the measures will be successful.
Two recent surveys of Arizona voters show growing majority support for an initiative to legalize adult-use cannabis.
Montana voters seem poised to approve a pair of marijuana legalization initiatives next month, according to a poll released last week.
In South Dakota, polling signals that voters will approve separate initiatives to allow both medical and recreational cannabis.
A survey of Mississippi voters that was released in September found that an activist-led measure to legalize medical marijuana “stands a strong chance of passage.”
Meanwhile, in New Jersey, putting legalization to voters as a referendum question was the result of the legislature’s failure to pass reform legislation last session.
Murphy, the governor, has been a vocal advocate for approving the measure.
He said during a virtual fundraiser with the pro-legalization NJ CAN 2020 earlier this month that the state “can’t fail” at enacting the policy change this round. A top lawmaker also spoke at the event and said an enabling and regulatory bill was being prepared in anticipation of a favorable vote, and that it could be voted on by the legislature as soon as the first week of November.
The governor also recently recorded a video ad that was released by the reform group, outlining why he’s embraced the policy change. Murphy said that the ongoing criminalization of cannabis in New Jersey wastes taxpayer dollars, and he emphasized that prohibition is enforced in a racially disproportionate manner.
Murphy similarly said in a recent interview that the marijuana reform proposal prioritizes social justice.
“I wish we could have gotten it done through a legislative process,” he said at the time, referencing lawmakers’ inability to advance a legalization bill last session. “We just couldn’t find the last few votes, so it’s on the referendum. I’m strongly supporting it—first and foremost for social justice reasons.”
Last month, Murphy also called on voters to support the proposal in an email blast that was circulated by the New Jersey Democratic State Committee.
“Legalization would right those wrongs while also spurring massive economic development opportunities, job creation, and new tax revenue,” the governor wrote. “Now, we have the opportunity to get this done and finally legalize adult-use marijuana here in the Garden State, and I need your help to make it happen.”
He said in July that legalizing cannabis is “an incredibly smart thing to do” both from an economic and social justice perspective.
The governor isn’t alone in his attempts to get out the vote for cannabis reform. Filmmaker Kevin Smith earlier this month urged his Twitter followers to “VOTE YES when you see State Public Question Number 1: Constitutional Amendment to Legalize Marijuana.”
NJ CAN 2020, one of two campaign committees working to pass the cannabis referendum, released a series of English- and Spanish-language video ads last week, after having published one prior ad. Meanwhile, campaign finance records compiled show that legal marijuana supporters are out-raising opponents by a ratio of nearly 130:1.
In June, the state Assembly passed a cannabis decriminalization bill that would make possession of up to two ounces a civil penalty without the threat of jail time, though it hasn’t advance in the Senate.
Photo courtesy of Philip Steffan.
Kamala Harris Touts ‘Commitment’ To Marijuana Decriminalization And Expungements Under Biden Administration
Democratic vice presidential nominee Kamala Harris (D-CA) again pledged in a new interview that decriminalizing marijuana would be an administrative priority if she and Joe Biden are elected.
Speaking to The Grio on Saturday, the senator discussed the would-be Democratic administration’s criminal justice agenda, contrasting it with that of President Donald Trump. She reiterated the cannabis reform would be among their policy goals.
“We have a commitment to decriminalizing marijuana and expunging the records of people who have been convicted of marijuana offenses,” Harris said. “When you look at the awful war on drugs and the disproportionate impact it had on black men and creating then criminal records that have deprived people of access to jobs and housing and basic benefits.”
Watch Harris discuss criminal justice and marijuana reform, starting around 12:00 into the video below:
While reform advocates have appreciated the senator’s repeated calls for cannabis reform on the campaign trail, they’ve taken issue with her tendency to refer to the drug war in the past tense—as she did here by talking about the impact the policy “had”—as though those prosecutions and enforcement disparities haven’t persisted.
In fact, recently released FBI data shows that there were 1,558,862 drug-related arrests in the U.S. last year, about a third of which were for marijuana. That amounts to a new drug bust every 20 seconds on average.
There’s also some frustration that Harris has scaled back her reform push since joining the Democratic ticket as Biden’s running mate. During her own run for the presidential nomination, she called for comprehensive marijuana legalization—a policy not supported by the former vice president despite its popularity among Democrats.
Harris, who is the lead Senate sponsor of a bill to federally deschedule marijuana, said last month that a Biden administration would not be “half-steppin’” cannabis reform or pursuing “incrementalism,” but that’s exactly how advocates would define simple decriminalization.
In any case, the senator has repeatedly discussed cannabis decriminalization on the trail. She similarly said during a vice presidential debate earlier this month that she and Biden “will decriminalize marijuana and we will expunge the records of those who have been convicted of marijuana.”
In addition to those policies, Biden backs modestly rescheduling the drug under federal law, letting states set their own policies and legalizing medical cannabis.
Photo element courtesy of California Attorney General’s Office.